^
    Back
    Association details:
    Biomarker:MLL-AFF1 fusion
    Cancer:Acute Lymphocytic Leukemia
    Drug:Koselugo (selumetinib) (MEK inhibitor) +
    entospletinib (GS-9973) (SYK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Haematologica
    Title:

    Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia

    Published date:
    05/15/2020
    Excerpt:
    As hypothesized, superior inhibition of ALL proliferation was observed in KMT2A-AFF1 PDX models treated with entospletinib and the MEK inhibitor selumetinib versus vehicle or inhibitor monotherapies (p<0.05).
    DOI:
    10.3324/haematol.2019.241729